Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTK 0796 in complicated skin and skin structure infection (cSSSI)
NCT03716024Phase 2Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Jul 2007
- Primary completion
- Jan 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of omadacycline in Complicated skin and skin structure infection (cSSSI) (2 arms), sponsored by Paratek Pharmaceuticals. Primary endpoints: Number of Participants With Clinical Response in the Modified Intent-to-Treat Population and Number of Participants With Clinical Response in the Clinically Evaluable Population. Started Jul 2007; status: completed.
02
Drugs
omadacycline
03
Conditions
Complicated skin and skin structure infection (cSSSI)
Beyond the preview
Go deeper on NCT03716024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716024.